Unigrace Pharmaceuticals Private Limited
About Unigrace Pharmaceuticals Private Limited
Data last updated:
Unigrace Pharmaceuticals Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the chemical products segment of the chemicals sector. It was incorporated on 13 April 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24299MH2016PTC279966. Its GSTIN is 27AABCU9247P1ZJ (Maharashtra).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Hitesh Chandrakant Bari and Shyamal Hitesh Bari.
Its last annual general meeting (AGM) was held on 29 September 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office is at Shop No. 8 Bhakti Park 'A' Wing Bhosale Nagar Shirgaon Badlapur(East) Tal: Ambernath, Mumbai, Maharashtra, India – 421503.
As per the financials filed for FY 2023, the company reported a revenue of ₹39,966, a decline of 51% compared to the previous year. For the same year it recorded a net loss of ₹2,907 (net margin -7.3%) and EBITDA of -₹48 (EBITDA margin -0.1%). Revenue has declined at a compounded annual rate (CAGR) of 77% over three years and 46% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Unigrace Pharmaceuticals Private Limited's registered office is in Mumbai, Maharashtra. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressShop No. 8 Bhakti Park 'A' Wing Bhosale Nagar Shirgaon Badlapur(East) Tal: Ambernath, Mumbai, Maharashtra, India – 421503
- IndustryChemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals
To see the full contact details of Unigrace Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Unigrace Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Unigrace Pharmaceuticals Private Limited, buy the company report.
Financials of Unigrace Pharmaceuticals Private Limited
FY 2023 filings availableUnigrace Pharmaceuticals Private Limited reported revenue of ₹39,966 (down 51% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 46% over five years, including a 51% fall in the latest year. EBITDA rose 100% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹48 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹2,907 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -0.1% | ||||
| Net Profit Margin | -7.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Unigrace Pharmaceuticals Private Limited, buy the company report.
Board of directors of Unigrace Pharmaceuticals Private Limited
Unigrace Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Hitesh Chandrakant Bari Also directs: Metrocare Pharma LLP, Ebis Pharma Private Limited | Director | 13 Apr 2016 | 10 Years 6 Months | Current |
| Shyamal Hitesh Bari | Director | 13 Apr 2016 | 10 Years 6 Months | Current |
Auditor
Unigrace Pharmaceuticals Private Limited is audited by SHALINI JAIN for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SHALINI JAIN | FY 2017 | 418467 |
Shareholding
The shareholding of Unigrace Pharmaceuticals Private Limited is on record for FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Foreign institutional investors (FII) | |
| Public | |
| Others |
To see the full shareholding pattern of Unigrace Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Unigrace Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Unigrace Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Unigrace Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCU9247P1ZJ | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Unigrace Pharmaceuticals Private Limited, buy the company report.
Recent activity
Unigrace Pharmaceuticals Private Limited has 2 board changes on record since 2016: 2 appointments. The latest: Hitesh Chandrakant Bari was appointed as Director on 13 Apr 2016.
Frequently asked questions
Unigrace Pharmaceuticals is an active private limited company based in Mumbai, Maharashtra, India. The company works in chemical products, within the chemicals industry. It was incorporated on 13 April 2016 (10+ years old) and is registered under CIN U24299MH2016PTC279966.
Unigrace Pharmaceuticals has 2 current directors:
- Hitesh Chandrakant Bari - Director
- Shyamal Hitesh Bari - Director
The latest financial statements of Unigrace Pharmaceuticals on record with the MCA are for the year ended 31 March 2023. Its last annual general meeting was held on 29 September 2023. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Unigrace Pharmaceuticals is 27AABCU9247P1ZJ, registered in Maharashtra.
The CIN (Corporate Identification Number) of Unigrace Pharmaceuticals is U24299MH2016PTC279966. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Unigrace Pharmaceuticals was incorporated on 13 April 2016, making it 10+ years old. It is registered with the Registrar of Companies, Mumbai.
Hitesh Chandrakant Bari was appointed as Director on 13 Apr 2016. Shyamal Hitesh Bari was appointed as Director on 13 Apr 2016.
The registered office of Unigrace Pharmaceuticals is at Shop No. 8 Bhakti Park A Wing Bhosale Nagar Shirgaon BadlapurEast Tal: Ambernath, Mumbai, Maharashtra, India – 421503.
Unigrace Pharmaceuticals operates in the chemicals industry, in the chemical products segment.
The compliance status of Unigrace Pharmaceuticals is compliant as of 03 August 2026. The company is actively filing with the Registrar of Companies.